Form 4: Aurinia Pharmaceuticals Director Karen L. Smith Reports Stock and Option Grants

Director Karen L. Smith of Aurinia Pharmaceuticals reported the acquisition of restricted stock units and stock options.

Summary

• Karen L. Smith, a director at Aurinia Pharmaceuticals, reported a transaction involving the acquisition of company securities.
• On November 21, 2024, Ms. Smith acquired 12,135 restricted stock units (RSUs) which are payable in common shares.
• These RSUs will vest one year from the grant date.
• Additionally, Ms. Smith acquired 18,641 stock options with an exercise price of $8.24 per share.
• These options also vest one year from the grant date and expire on November 21, 2034.
• Following these transactions, Ms. Smith directly owns 24,807 common shares and 18,641 stock options.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock and option grants to a director, which is generally viewed as a neutral to slightly positive event as it aligns management interests with shareholders.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of shareholders.
• The vesting period of one year for both the RSUs and options encourages long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders such as directors or officers make transactions in the company's securities. It is a routine disclosure required by law to ensure transparency in the market.

Comparison to Industry Standards

• The granting of stock options and restricted stock units to directors is a common practice in publicly traded companies to align their interests with shareholders.
• The vesting period of one year is also a typical timeframe for such grants.
• Companies like Gilead Sciences, Biogen, and Vertex Pharmaceuticals also use similar compensation methods for their directors and executives.

Stakeholder Impact

• The stock and option grants to a director may have a slightly positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Aurinia Pharmaceuticals, Director, Karen L. Smith, Stock Options, Restricted Stock Units, RSUs, Securities, Insider Trading, Form 4